catalpol has been researched along with exenatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, H; Gong, N; Ma, AN; Wang, YX; Xiao, Q | 1 |
| Gong, N; Jia, Y; Li, TF; Wang, YX; Zhu, B | 1 |
2 other study(ies) available for catalpol and exenatide
| Article | Year |
|---|---|
Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors.
Topics: Analgesics; Animals; Central Nervous System Agents; Exenatide; Formaldehyde; Glucagon-Like Peptide-1 Receptor; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; Iridoid Glucosides; Iridoids; Male; Mice; Nociception; PC12 Cells; Peptide Fragments; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Spinal Cord; Venoms | 2014 |
Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
Topics: Animals; beta-Endorphin; Cells, Cultured; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hippocampus; Insulin; Iridoid Glucosides; Male; Microglia; Neurons; Neuroprotection; Neuroprotective Agents; Peptides; Rats; Rats, Wistar; Receptors, Opioid; Venoms | 2015 |